Clinical trials located in

Louny

Louny city is located in Czechia. Currently, 6 clinical trials are being conducted in this city.

Louny, nestled in the Czech Republic, is a city rich in architectural beauty and history. Founded in the 12th century, it boasts a well-preserved medieval center. The Gothic Church of St. Nicholas and the Renaissance town hall highlight its architectural heritage. Louny is also known for its part in the Hussite Wars, adding a layer of historical significance. Surrounded by fertile lands, it’s a gateway to exploring the picturesque landscapes of the Ústí nad Labem Region. The city’s blend of history, architecture, and natural beauty makes it a notable spot in Czechia.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Baxdrostat in resistant hypertension: safety and efficacy study

    This study is testing a medication named baxdrostat in people who have high blood pressure that can’t be controlled with their current medication. The study will compare people who are given baxdrostat daily with people who are given a placebo. The goal of the study is to find out if baxdrostat is safe to take and if it helps lower blood pressure. The study will look at the effects of 1 mg and 2 mg doses of baxdrostat on blood pressure. The study will also look at whether Baxdrostat helps reach a blood pressure reading below 130 mmHg.

    • Baxdrostat
  • Asthma control study: comparing two inhalers over 12 weeks

    This study compares two inhalers for asthma control over 12 weeks. One combines budesonide and formoterol fumarate, and the other contains only budesonide. Around 340 adults and teens with poorly controlled asthma despite current treatment will participate. The study measures lung function, asthma symptoms, and medication safety. It’s a double-blind trial, meaning neither participants nor researchers know who receives which inhaler.

    • Budesonide (BD)
    • Formoterol Fumarate
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Czechia:

.